RD-BIOTECH
keyboard_backspaceBack to Home
Contact
Technopole TEMIS Santé, 18 rue Françoise Dolto
25000 Besançon
France
Marketing Manager
About us
RD-BIOTECH is an international CRO/CDMO that provides services in molecular biology, immunology, and cell engineering for both R&D stages and preclinical and clinical development phases of innovative therapy biomolecules:
- Plasmid DNA: Cloning and vector construction, pDNA biomanufacturing, Research, High Quality and GMP grades.
- Monoclonal and recombinant ANTIBODIES: Biomanufacturing, Research and High Quality grades.
- Recombinant PROTEINS: From vector construction to bioproduction in the best expression system, Research and High Quality grades.
Compliant with ISO 9001:2015 Quality Standards and leveraging a high level of expertise and skills developed over more than 20 years, RD-Biotech is a trusted partner for the development and production of essential raw materials for cell and gene therapies: plasmid DNA, monoclonal antibodies, recombinant proteins... The establishment of its new GMP-grade plasmid DNA production unit in 2023 further solidifies RD-Biotech's position as a leading biomanufacter in France.
For more information, please visit our website www.rd-biotech.com or contact us: info@rd-biotech.com
Business offer
1 - Plasmid DNA platform from engineering to manufacturing – Design and cloning of plasmid vectors – Production of pDNA, from pilot batches of a few mg to large-scale productions of up to 20 g – Several Quality grades: R&D, High Quality and GMP Quality.
2 - Antibody engineering platform: Development and production of monoclonal antibodies (hybridomas) – Antibody sequencing and development of recombinant antibodies – Production of pilot batches of a few mg up to large-scale production (several grams) – Quality R&D and High Quality
3 - Expression platform for recombinant proteins in different systems (prokaryotic, eukaryotic, yeast, cell-free)
Activities
- Service
- Immunotherapy lead optimization
- Engineering
- Protein scaffolds
- Fragments
- Multi-, bispecific
- Fc-fusion proteins
- Antibody humanization
- Affinity maturation
- Bioproduction
- Batches production type
- Mammalian
- Yeast
- Bacterial
- GLP compliance
- Pilot Batches
- Tests
- Optimization
- Scale-Up process
- Process optimization & validation
- Volume
- Preclinical / Tox
- Low volume (< 200 L)
- High volume (200 – 2000 L)
- USP (Scale-Up)
- Cell expansion
- Inoculation
- Low volume containers to Bioreactors
- DSP (Recovery)
- Harvest
- Filtration
- Purification
- Gene Cloning
- (Gene) engineering
- Binder Generation
- Hybridoma
- Bioproduction/CMC/Analytical Quality Assessment, Quality Control
- Bioproduction
- Non-GMP pilot batch
- GMP batch
- Antigen-protective immune-response profile
- Humoral response characterization:
- Antibody dosage
- Vaccine: antigen format platforms
- Recombinant protein expression
- Bacterial
- Cell
- DNA plasmid vaccine
- mRNA vaccine
- Other
- Bioproduction GMP
- Vaccine platform type
- Recombinant protein expression
- Viral vector encoding target antigen
- DNA plasmid vaccine
- mRNA vaccine
- Other
- Manufacturing Volume
- Small volume (< 100 L) adjusted to phase I/II needs: specify volume
